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Pulmonary infection due to chronic microbial
colonization is the major cause of illness and
death in cystic fibrosis (CF) patients. Mucoid
Pseudomonas aeruginosa, which is involved in
pulmonary damage, is the most frequently
recovered pathogen. In contrast, little informa-
tion is available about the role of other nonfer-
mentative  gram-negative rods. An increasing
incidence of Stenotrophomonas maltophilia iso-
lates has been reported in some CF centers during
the last decade (1-4). Although an association
between  S. maltophilia colonization and lung
damage has been observed (2,3), the role of the
organism is still undetermined (5,6). In non-CF
patients (e.g., immunocompromised or intensive-
care unit patients), exposure to wide-spectrum
antimicrobial drugs, long-term antimicrobial ther-
apy, previous pulmonary infections, and chronic
respiratory disease contribute to S. maltophilia
acquisition and increase the risk for respiratory
infection with this organism (7,8). All these risk
factors are present in the CF population.
We analyzed S. maltophilia from respiratory
isolates of 25 CF patients of the same CF unit
during an 8-year period to determine a) the
overall and yearly incidence of S. maltophilia
infection or colonization and incidence as
determined by molecular typing, ribotyping, and
pulsed-field gel electrophoresis (PFGE); b) the
age distribution of acquisition of S. maltophilia
pulmonary infection or colonization in patients
with single or repeated episodes; c) the
persistence and variability of S. maltophilia
isolates in patients who had more than one
episode and the degree of genomic similarity
identified among clones; and d) the epidemiologic
link between similar isolates from different
patients. We also investigated pulmonary
function and other clinical aspects of
S. maltophilia-infected or colonized patients.
Materials and Methods
From 1991 to 1998, 25 CF patients (12 female
and 13 male) of 104 who were clinically and
microbiologically followed at the Hospital Ramón
y Cajal CF Unit had at least one positive
respiratory culture for S. maltophilia. CF was
diagnosed by a positive sweat chloride test
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(>60 mEq/L) in association with typical pulmo-
nary and gastrointestinal findings or a positive
family history. The age range of patients was <1
to 32 years (median 14.5 years). Eleven patients
were homozygotes and eight heterozygotes for
∆ F508, the most common mutation in the cystic
fibrosis transmembrane conductance regulator
(CFTR) gene, and one patient was negative for
∆ F508. Mutation in this gene could not be
determined in five patients. The mean number of
sputum samples examined was 6.7 specimens per
patient per year. All 25 patients were followed for
at least 1 year during the study period (range 1 to
8 years, mean 5.8 years). Culture results were
used to establish age at acquisition of
S. maltophilia. When available, retrospective
cultures obtained before 1991 were also taken
into account.
S. maltophilia colonization in CF patients
was considered persistent if positive cultures
were obtained for >6 months, regardless of
bacterial counts. Overall incidence was defined
as the number of patients infected or colonized
with S. maltophilia, independent of the number
of positive cultures during the study period. The
denominator was the total number of patients
seen at the CF unit (104 patients). Yearly
incidence was defined as the number of patients
with new episodes of S. maltophilia infection or
colonization, with the denominator the number of
patients seen per year in the CF unit. The overall
incidence and yearly incidence were recalculated
when molecular typing data were available. These
values were defined as overall clonal incidence and
yearly clonal incidence, respectively, which
represent the incidence of S. maltophilia episodes
caused by different clonal strains.
Bacteriologic Study and S. maltophilia Isolates
Respiratory secretions, mostly expectorated
sputum, were homogenized with N-acetyl-
cysteine and processed by a modified quantita-
tive technique (9). Columbia 5% blood,
MacConkey, mannitol and salt, and a selective
Burkholderia cepacia agar media were incubated
in air for 24 hours at 37°C, followed by 24 hours at
25°C. In addition, bacitracin-chocolate agar was
plated and incubated in 5% CO2 for 48 hours and
Sabouraud-chloramphenicol and Sabouraud-
chloramphenicol-cyclohexamide agar media for 4
weeks at 30°C and 37°C. A culture for
S. maltophilia was considered positive when any
growth of this organism was observed, regardless
of bacterial count. Biochemical identification of
S. maltophilia isolates was performed both with
the API 20NE gallery (BioMerieux, Marcy-
l´Étoile, France) and the semiautomatic PASCO
system (Difco, Detroit, MI). Bacterial counts and
co-colonization with other respiratory pathogens
were also considered in the analysis. The same
microbiologic protocol was applied to all patients,
regardless of clinical condition.
Ribotyping
DNA from all S. maltophilia isolates was
prepared by treatment with hexadecyl-
trimethylammonium bromide (10). Ribotyping
was performed as described (11). BamH1,
Bsu15I, EcoRI, and HindIII restriction endonu-
cleases (Roche Diagnostic, Mannheim, Germany)
were also tested in a representative number of
isolates. The best-defined restriction pattern
with a higher number of bands was observed with
BamH1 and HindIII. Digoxigenin-labeled phage
λ HindIII-digested DNA (Roche) was used as a
molecular size marker. DNA fragments were
separated by electrophoresis in 0.7% agarose gels
and were blotted onto nylon membranes.
Membranes were hybridized with a digoxigenin-
labeled rRNA probe with 16S+23S rRNA
sequences of Escherichia coli (Roche) at 68ºC for
18 hours (12). Differences in numbers and the
position of bands were considered.
Pulsed-Field Gel Electrophoresis
S. maltophilia DNA was prepared and
contained in agarose plugs for digestion with 30
U of XbaI (Roche). Closely related isolates using
XbaI were reanalyzed with 20 U of SpeI (Roche)
as described (13). Digested samples were melted
and loaded onto 1% agarose gels. PFGE was
performed with the CHEF-DRII system (Bio-
Rad, Hemel Hempstead, UK). Standard lambda
ladders comprising 48.5-kbp concatemers were
run as molecular weight markers (Roche).
Electrophoresis pulse times for XbaI-digested
DNA were 10 to 60 seconds for 24 hours, followed
by a second ramp from 5 to 20 seconds for 5 hours.
Both ramps were performed at 5.4 V/cm and 12º
C. For SpeI, pulse times were 25 to 45 seconds for
20 hours at 6 V/cm and 12°C. Macrorestriction
fragments were visually compared and interpreted
according to the criteria of Tenover et al. (14).
A genetic similarity dendogram was designed
and calculated by the Dice correlation coefficient
(15) and represented by UPGMA with Molecular115 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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Analyst Software (BioRad) and a tolerance
position of 1%. Only well-resolved bands
corresponding to fragments exceeding 97.0 kbp
were included in the computer analysis.
Patient Data
Chart records from S. maltophilia-positive
CF patients were reviewed. Patients were
classified according to age, sex, and severity of
lung disease. Correlation between colonization or
infection with S. maltophilia and pulmonary
function was studied. Pulmonary function was
tested in accordance with American Thoracic
Society Guidelines (16). Forced expiratory
volume (FEV1) (% predicted) value was expressed
as the percentage predicted according to
Knudson norms for adjusting data for age,
height, and sex (17). Trends in FEV1 were
estimated by comparing values at the time of the
first recovery of S. maltophilia with those
obtained within a year from the last isolation.
P. aeruginosa and other pathogens commonly
encountered in CF were also recorded as outcome
criteria for evaluating the progression of
pulmonary disease.
Statistic Analysis
Statistical significance for comparison pro-
portions was calculated by Chi square or Fisher’s
exact test with Epi-Info 6.04a. Quantitative
values were compared by Student’s t test; p<0.05
was considered statistically significant.
Results
From 1991 to 1998, at least one respiratory
culture positive for S. maltophilia was observed
in 25 of 104 patients. Thus, the overall incidence
of S. maltophilia-infected or -colonized patients
was 24%; yearly incidence was 2.9% to 14.0%
(Figure 1). Fourteen (56%) of these 25 patients
had a single episode of S. maltophilia (SM-SE
group), and 11 patients (44%) had repeated
episodes (SM-RE group). No differences in
sampling frequency (number of sputum samples
studied per year) or length of follow-up were
found between the two groups.
Eighty-eight  S. maltophilia isolates were
recovered from these 25 patients. Seventy-six
isolates, 14 from the SM-SE group and 62 from
the SM-RE group, were available for further
study. PFGE results indicated an overall clonal
incidence of 47.1%, reflecting new strains with
different PFGE profiles that had been acquired
by the SM-RE group (Figure 1). The highest
yearly clonal incidences were detected in 1991
and 1996.
In the SM-SE group, the median age at
acquisition of S. maltophilia was 13.4 years
(range <1 to 27 years). Nearly 43% of patients (6
of 14) acquired S. maltophilia at 6 to 10 years of
age (Figure 2). In SM-RE patients, the median
age at first S. maltophilia isolation was 16.7
years (range 3 to 32 years). In this group, 45% (5
of 11) acquired S. maltophilia at 11 to 20 years of
age. PFGE analysis of all S. maltophilia strains
Figure 1. Yearly
incidence, yearly
clonal incidence,
and yearly preva-
lence of Stenotro-
phomonas malto-
philia acquisition
in 104 cystic fibro-
sis patients, 1991–
1998.116 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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indicated that nine new acquisitions occurred in
11- to 15-year-old patients. Because of the small
sample size, differences in age of acquisition
between the groups could not be demonstrated
with statistical significance.
Ribotyping
To select the suitable enzyme(s) for
S. maltophilia ribotyping, BamH1,  Bsu15I,
EcoRI, and HindIII endonucleases were used in
five different strains isolated from the same
patient, resulting in 4, 4, 2, and 4 different
ribotypes, respectively. The number of copies of
the ribosomal rRNA operon in S. maltophilia was
2 to 5 per isolate for BamHI, 2 to 4 Bsu15I for
HindIII, and 4 to 5 for EcoRI, with hybridization
band sizes of 3 Kbp to 20 kbp. Great
heterogeneity in ribotypes, 21 with HindIII and
20 with BamHI, was found among the 76 S.
maltophilia isolates, with a Simpson index (15) of
0.8992 and 0.9158, respectively. The genetic
similarity was 29% to 100% for HindIII and 38%
to 100% for BamHI.
PFGE Analysis
Forty-seven well-defined profiles of genomic
DNA under XbaI digestion were obtained from
the 76 S. maltophilia isolates. According to Tenover
criteria (14), 41 types and 6 subtypes were
considered. These 6 subtypes were associated
with 3 of the 41 main subtypes. Fragment size
was <48 kbp to >1,000 kbp. Discrimination based
on Simpson´s index peaked at 0.97. Genetic
heterogeneity is illustrated by the dendogram of
the 47 XbaI-PFGE profiles (Figure 3). Repeated
isolates displaying an identical PFGE profile from
Figure 2. Distribution of age of acquisition of
Stenotrophomonas maltophilia in 25 cystic fibrosis
patients with a single episode (SM-SE group) or with
repeated episodes (SM-RE group).
Figure 3. Percentages of genetic similarity between 47
XbaI-PFGE clonal types from 76 Stenotrophomonas
maltophilia  strains isolated in 25 cystic fibrosis
patients of the same unit, 1991–1998.117 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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the same patient or resulting from presumed
patient-to-patient transmission were excluded
from the dendogram. Forty-one types displayed
similarity coefficients from 25% to 75%; each was
coded with a number. Each subtype was coded
with a letter (similarity  >80%). Strains sharing the
same XbaI digestion pattern could not be further
distinguished by SpeI. XbaI was more efficient
than SpeI in distinguishing between subtypes or
closely related strains; 14a and 14b subtypes
showed an indistinguishable PFGE pattern with
SpeI. This was also the case with 16a and 16c
subtypes.
Persistence and Variability
of S. maltophilia Strains
The SM-SE group of 14 patients had 14
different PFGE types. One of these PFGE
patterns (pattern 1a) was also seen in two of the
SM-RE patients (patients 1 and 3). During the
study period, each of the 11 patients in the SM-
RE group had one to five strains with different
PFGE profiles. Strains from five patients (1, 3, 8,
10, and 11) completely met the criteria for
persistence (Figure 4). The strains were
recovered from these patients during periods of
persistence of 29, 86, 6, 9, and 8 months,
respectively. A turnover of this predominant
strain with a different strain occurred in four of
these patients. In patient 4, two strains with 4
and 32 months of persistence were isolated
during two different periods. All these patients
were considered persistently colonized with
identical  S. maltophilia isolates (Figure 4).
Variable colonization, defined as the isolation of
S. maltophilia strains with different PFGE
Figure 4. Persistence and variability of Stenotrophomonas maltophilia strains in 11 patients with repeated
episodes of infection or colonization with this organism. S. maltophilia recovered is indicated by a ♦   (identical
isolates from the same patient), ◊   (different isolate from a single patient) or O (no isolate available). Distinct
S. maltophilia isolates are identified by numbers, and a letter was added when a closely related strain was
observed.  + = time at which sputum specimens were obtained.118 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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Table. Demographic characteristics and co-colonization status of cystic fibrosis patients with Stenotrophomonas
maltophilia infection or colonization
Characteristics SM-SEa (14 patients) SM-REb (11 patients)
Gender
Male   8   5
Female   6   6
Patient genotyped 11   9
Homozygous ∆ F508   8   3
Heterozygous  ∆ F508   3   5
Other   0   1
Mean age at first S. maltophilia isolation (SD, years) 13.4 (7.3) 16.7 (7.4)
FEV1
c  measured 11 10
FEV1  (% predicted) before S. maltophilia recovery (Mean [SD]) 68.7 (29.6) 74.2 (28.3)
>100   2   1
70–99   3   5
40–69   4   3
<40   2   1
FEV1  (% predicted) after S. maltophilia recovery (Mean [SD]) 63.8 (20.7) 62.9 (24.2)
ABPAc condition   2   1
Death (%)   4    (28.5)   2    (18.2)
S. maltophilia bacterial counts (geometric mean, cfu/mL)   8.4 x 104 d   2.9 x 108 d
Pseudomonas aeruginosa detected (%) 12    (85.7)   9    (81.8)
Aspergillus detected (%)   7    (50.0)   7    (63.6)
S. maltophilia co-colonization with:e
Only S. maltophilia detected (%)   1    (7.1)   1    (9.1)
P. aeruginosa (%)   8    (57.1)   3    (27.2)
Staphylococcus aureus (%)   6    (42.8)   3    (27.2)
Burkholderia cepacia (%)   1    (7.1)   1    (9.1)
Aspergillus spp. (%)   1    (7.1)   3    (27.2)
Candida (%)   3    (21.4)   2    (18.2)
aSM-SE = CF patients with a single episode of S. maltophilia colonization.
bSM-RE: CF patients with repeated episodes of S. maltophilia colonization.
cFEV = Forced expiratory volume.
dABPA: allergic bronchopulmonary aspergillosis.
ep<0.05 comparing both groups.
fPatients in the SM-RE group colonized with organisms in addition to S. maltophilia. When different co-colonizations occurred
in the same patient, we recorded only the cocolonization that was at least twice as frequent.
profiles, was identified in five patients (patients
2, 5, 6, 7, and 9).
Suspected Cross-Transmission
In 1996, three patients, two in the SM-RE
group (patients 1 and 3) and another (patient 12)
in the SM-SE group, shared S. maltophilia
isolates with indistinguishable ribotype and
PFGE type under all restriction enzymes tested
(profile 1a). Patient 1 was persistently colonized
with this strain for 2 years, and patient 3 was
transiently colonized (Figure 4).
Bacterial Counts and Clinical Findings
SM-SE patients had higher S. maltophilia
bacterial counts when either the first
S. maltophilia isolate (geometric mean, 4.3 x105
cfu/mL) or all isolates (2.9 x108 cfu/mL) were
taken into account (p<0.05), compared with
patients with a single episode (8.4 x104 cfu/mL). A
similar rate of P. aeruginosa recovered from the
respiratory tract during the study period was
noted in both groups (Table). In contrast,
Aspergillus spp. was detected more frequently in
the SM-RE group of patients. No statistical
differences were found when co-colonization was
evaluated. However, S. maltophilia co-coloniza-
tion with Aspergillus spp. in the SM-RE group
had a risk ratio of 3.8 compared with the SM-SE
group.
Demographic and selected medical charac-
teristics and results of respiratory tract cultures
were analyzed for S. maltophilia-infected or -
colonized patients (Table). Before S. maltophilia
colonization, slightly lower pulmonary function
levels (FEV1, % predicted) were observed in
patients with a single S. maltophilia episode
than in patients with repeated episodes (Table).119 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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This value decreased in SM-RE patients from
74.2 ± 28.3 (mean value ± SD) (first isolation
of S. maltophilia) to 62.9 ± 24.2 (last isolation of
S. maltophilia), which could indicate a decreas-
ing trend in FEV1 after the first episode.
However, this difference was not statistically
significant. On the other hand, SM-SE patients
had a higher death rate (28.5%) than the SM-RE
group, but death rates in both groups were higher
than those observed in S. maltophilia-negative
patients (12.6%).
Conclusions
S. maltophilia, an essentially environmental
organism, is the fourth organism in prevalence in
bronchial secretions of CF patients, after
P. aeruginosa, Staphylococcus aureus, and
Haemophilus influenzae (5,18). Since it was first
reported in CF patients in 1979 (19), this
organism has been investigated for its role in the
progression of CF pulmonary disease (5), and
consensus documents have emphasized the
importance of clinical microbiology laboratories
in detecting its presence in CF respiratory
secretions (20). Despite some virulence factors
shared with P. aeruginosa, its potential for
pathogenicity remains uncertain (21). We have
reported a high incidence of S. maltophilia-
colonized CF patients (30.7%) over a 5-year
period (3), but, as in other studies (2,6,22), we did
not address (through epidemiologic typing
studies) whether this high rate was a conse-
quence of patient-to-patient transmission or
whether bacterial colonization was sporadically
or chronically established.
The 1997 Cystic Fibrosis Foundation Patient
Registry from the United States (18), which
included 17,996 CF patients in a cross-sectional
study analyzing one respiratory sample per
patient per year, showed a percentage of positive
cultures for S. maltophilia of 5.1%, a value
slightly higher than in 1996 (3.9%) and 1995
(3.4%). In our study, the overall incidence, 24%, is
higher than that observed in other studies (10.6%
to 16.6%) with a similar length of follow-up (2,22),
but slightly lower than in studies with a longer
follow-up period (27.3%) (6). Consistent with
other results, our data showed no clear trend
towards increasing or decreasing over the study
period (Figure 1).
The main purpose of our study was to apply
molecular typing, both with ribotyping and
PFGE, to S. maltophilia isolates recovered from
patients seen in our CF Unit. Among 76 isolates,
47 PFGE profiles were identified, and these
results were used to calculate the incidence of
episodes of S. maltophilia colonization or
infection in our series. Without typing, the
overall incidence was 24% for the entire study
period; by PFGE the incidence was 47.1%. This
result clearly indicates that SM-RE patients had
new episodes with different S. maltophilia
strains. Molecular typing also differentiated
patients who were chronically infected or
colonized with the same strain (persistence) from
those with repeated episodes with different
S. maltophilia strains (variability).
PFGE has been recommended for epidemio-
logic studies of S. maltophilia isolates (13,23-25).
The technique has been shown to be more
discriminatory than enterobacterial repetitive
intergenic consensus polymerase chain reaction
and other molecular techniques for differentia-
tion within this species (13). In our study,
restriction endonuclease XbaI provides discrimi-
natory patterns, with a high discrimination value
on Simpson´s index (0.97), enabling easy
interpretation of banding profiles. This enzyme
has been used to study the stability of
S. maltophilia from a CF patient over a 15-month
period (26), the relationship between CF and
environmental S. maltophilia isolates (13), and
the epidemiology of S. maltophilia isolates from a
hematology department (27). Other studies have
been based on DraI (25,28,29) and SpeI
(23,27,30). In our study, XbaI was more efficient
than SpeI in distinguishing between subtypes or
closely related strains.
We observed only one positive culture of
S. maltophilia over the study period in 14
patients, in accordance with the results of Demko
et al. (6), who showed that 50% of CF patients had
only one positive culture of S. maltophilia over a
13-year period. In contrast, 11 patients (44%)
from our CF unit had repeated episodes of
S. maltophilia colonization or infection. Typing
studies, however, demonstrated different strains
in five patients and, with the exception of patient
8, a persistent strain was characterized in the
remaining six patients, but with a turnover with
distinct strains (Figure 4). Because of sampling
bias, some of these patients may also have had
persistent colonization. Of 11 patients with
repeated SM-RE isolates, 6 had evidence of
persistent colonization (Figure 5). More frequent
sampling could have increased this proportion.120 Emerging Infectious Diseases Vol. 7, No. 1, January–February 2001
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Cross-transmission was suspected in three
patients who shared isolates with an identical
PFGE profile. No overlapping hospitalizations,
clinical visits, or other epidemiologic relationship
were demonstrated in these patients. Recently,
Alfieri et al. (30) reported cross-transmission of
S. maltophilia in non-CF patients during two
consecutive nosocomial outbreaks in an intensive
care unit, but an environmental ventilator isolate
was temporally associated with infection.
Heterogeneity is also illustrated among
S. maltophilia isolates recovered from the same
patient. SM-RE patients 2, 5, 6, 7, and 9 were
colonized at different times by different clones
with PFGE similarity genetic coefficients of 24%
to 61%. Among S. maltophilia isolates recovered
from different patients, the genetic coefficient
range was even wider (25% to 75%). This
heterogeneity could result from acquisition from
different environmental sources, probably out-
side the nosocomial setting. In fact, a high
diversity of S. maltophilia isolates has also been
confirmed in the environment (13,25). The
precise mode of acquisition of S. maltophilia in
CF patients has not been determined, but
different studies strongly suggest that faucets,
ventilators, sink drains, and other devices
frequently in contact with water could be
common sites of contamination (13,25,28,30,31).
In most cases, chronic colonization with
P. aeruginosa occurs with a single strain, which
undergoes phenotypic variation over time (32).
This changing adaptive response is probably
driven by stressful conditions of the lung
environment for bacterial organisms and results
from the selection of hypermutable genetic
variants (33). In the case of S. maltophilia, the
isolation of the same clonal type after years of
apparent absence suggests a long low-grade
persistence that could not be detected by
microbiologic culture. In patient 3, the same
strain was isolated 11 times over a 7-year period
without change in its PFGE profile. The differing
subtypes in patients 1, 10, and 11 may be
accounted for by genetic events during chronic
colonization (Figure 4).
The 1997 Cystic Fibrosis Patient Registry
Annual Report (18) showed that S. maltophilia
respiratory colonization was 3.1% to 8.6% in
patients 2 to 5 and >45 years of age, respectively,
with a clear increase in patients >35 years of age.
We analyzed the age at first acquisition of an
S. maltophilia isolate, including all 25 patients
with at least one positive culture for this
organism during the study period. When
available, a retrospective review of cultures
obtained before 1991 was also taken into account.
Colonization rates were 4% to 24% in the 31-35
and 16-20 age groups, respectively. The peak age
of acquisition was 16-20 years, as reported by
Demko et al. (6), but the two groups of
S. maltophilia-colonized patients, SM-SE and
SM–RE, differed in age of acquisition. In SM-SE
patients, peak age of acquisition was 6 to 10 years
(42.8%); in the SM–RE group it was 16 to 20 years
(27.2%). These results suggest that S. maltophilia
colonization in younger CF patients could be an
isolated event, whereas chronic colonization with
this organism occurs more frequently when
acquired in 16- to 20-year-old patients.
Higher significant (p<0.05) differences in
S. maltophilia bacterial counts were obtained in
patients persistently colonized with this organ-
ism compared with those with single episodes,
suggesting that the colonizing ability of a given
strain may be a marker for future persistence. In
addition, the former group had a decline in
pulmonary function as indicated by FEV1  (%
predicted) values closest to the first and last
S. maltophilia isolations. Reduction in pulmonary
Figure 5. Pulsed-field gel electrophoresis pattern of XbaI-
digested genomic DNA of Stenotrophomonas maltophilia
isolates from two SM-RE patients. Lanes 1-10 from
patient 1 (persistence group): pattern 1a (lanes 1,3-6,8),
pattern 1b (ln 7), pattern 1c (lane 9) and pattern 2 (lane
2); lanes 10-15 from patient 5 (variability group): pattern
3 (lane 10), pattern 4 (lane 11,12), pattern  5 (lane 13),
pattern 6 (lane 14), pattern 7 (lane 15). Lanes M,
bacteriophage lambda standard marker.121 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
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function could also reflect increased age or the
effect of other pathogens. In fact, a higher rate of
Aspergillus  spp. isolation was detected in CF
patients chronically colonized with S. maltophilia.
However, a higher death rate was observed in
patients with a single episode of S. maltophilia
(28.5%) than in patients with repeated episodes
(18.2%), but both these values were higher than
those obtained in S. maltophilia-negative
patients (12.6%). Demko et al. recently reported a
lower death rate in patients with long-term
chronically  S. maltophilia-positive cultures
(7.7%) than in those with transient or acute
positive cultures (21.1%)(6). Moreover, the
combined death rate in S. maltophilia-positive
patients (19.0%) was slightly higher than in
S. maltophilia-negative patients (16.5%). In
contrast, Goss et al. (34) demonstrated in a cohort
study that S. maltophilia acquisition did not
decrease survival in patients with CF, but
patients with this organism had significantly
lower FEV1  (% predicted) values. These data
suggest that isolation and persistence of
S. maltophilia could contribute to a progression
of clinical deterioration, particularly in patients
with lower pulmonary function. Increased
S. maltophilia colonization may be observed in
the future as a result of improvements in life
expectancy.
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